DaVita stock faces volume headwinds as non-dialysis growth offsets

Published on 11/12/2026 at 02:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DaVita stock faces softer dialysis volumes after higher hospitalizations. Integrated kidney care and international operations are expected to support earnings.

Growth offsets operating pressure

DaVita expects fourth-quarter operating income to rise by about 30 million US dollars sequentially, led by non-dialysis businesses.
Management sees a 1.5 to 2 percent Medicare rate increase in 2027, while exchange coverage changes remain a headwind.
New dialyzer technology is being rolled out to improve middle-molecule clearance and patient outcomes over time.

DaVita Inc., US23918K1088, Illustration mit AI erstellt.

DaVita management pointed to softer dialysis volumes but stronger non-dialysis businesses at the Wolfe Research Healthcare Conference on Tuesday, November 10, 2026. In a report by Investing.com, Chief Financial Officer Joel Ackerman said third-quarter treatment volume was about 20 basis points below expectations because of higher hospitalizations and missed treatments.

DaVita stock traded at 165.48 euros on Lang & Schwarz at 11:00 p.m. CET on Wednesday, November 11, 2026.

Non-dialysis businesses carry earnings

Management expects fourth-quarter operating income to increase by about 30 million US dollars from the third quarter. The entire sequential gain is expected to come from integrated kidney care and international operations, while the dialysis business is expected to remain broadly flat despite a material calendar-related volume decline.

DaVita said its integrated kidney care business has outperformed expectations in 2026 and should contribute 20 million to 25 million US dollars in annual operating income going forward. The company also said international operations remain a growth contributor, although third-quarter results benefited from non-recurring divestitures in Brazil.

Reimbursement remains a key swing factor

Management expects a 1.5 to 2 percent Medicare rate increase in 2027, with the final outcome depending partly on the treatment of TDAPA add-on payments. Medicare Advantage negotiations are becoming more important as the business becomes less dependent on fee-for-service reimbursement.

DaVita also expects a 70 million US dollar headwind in 2027 from lower commercial insurance exposure among new patient starts and the annualization of 2026 changes. The company has not issued formal 2027 guidance and said several operating and reimbursement variables remain unresolved.

New technology targets patient outcomes

DaVita is rolling out new dialyzers designed to clear middle molecules more effectively while preserving proteins such as albumin. The company expects the technology to reach the vast majority of eligible patients in November and believes improved patient outcomes could support volume trends over the next several years.

DaVita's healthcare platform

DaVita provides kidney care across in-center and home dialysis, integrated kidney care, clinical research and physician-support services. The company serves dialysis patients in the United States and 14 countries outside the United States. In US dialysis, DaVita is a major provider alongside Fresenius Medical Care, while its integrated and international activities give it a broader operating mix than a single-service dialysis model.